Health Condition 1: P039- Newborn affected by complication of labor and delivery, unspecified
Conditions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: All neonates born above 36 weeks of gestation with evidence of intrapartum asphyxia (APGAR score: 12mmmol/L) and presence of moderate or severe hypoxic-ischemic encephalopathy as per modified Sarnat and Sarnat staging undergoing Therapeutic Hypothermia are included.
Exclusion criteria
Exclusion criteria: Neonates < 36 weeks and birth weight <1.8 kg with evidence of intrapartum asphyxia are excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of aminophylline in neonates with moderate to severe encephalopathy undergoing Therapeutic Hypothermia. Timepoint: at 12 Hours of Life at 72 Hours of Life | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. To assess optimal dosing strategies, importance of timing and duration of exposure of aminophylline, in neonates with moderate to severe encephalopathy during Therapeutic Hypothermia.Timepoint: at 12 Hours of Life at 72 Hours of Life | — |
Countries
India
Contacts
BLDE(DU) SHRI B M PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTER, VIJAYAPURA